396 related articles for article (PubMed ID: 35006466)
1. Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.
Girisa S; Henamayee S; Parama D; Rana V; Dutta U; Kunnumakkara AB
Mol Biomed; 2021 Jul; 2(1):21. PubMed ID: 35006466
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration.
Li G; L Guo G
Acta Pharm Sin B; 2015 Mar; 5(2):93-8. PubMed ID: 26579433
[TBL] [Abstract][Full Text] [Related]
3. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
4. Differential roles of farnesoid X receptor (FXR) in modulating apoptosis in cancer cells.
Girisa S; Rana V; Parama D; Dutta U; Kunnumakkara AB
Adv Protein Chem Struct Biol; 2021; 126():63-90. PubMed ID: 34090620
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis.
Liu H; Pathak P; Boehme S; Chiang JL
J Lipid Res; 2016 Oct; 57(10):1831-1844. PubMed ID: 27534992
[TBL] [Abstract][Full Text] [Related]
6. Effects and mechanism of the bile acid (farnesoid X) receptor on the Wnt/β-catenin signaling pathway in colon cancer.
Mao J; Chen X; Wang C; Li W; Li J
Oncol Lett; 2020 Jul; 20(1):337-345. PubMed ID: 32565960
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.
Chen B; You WJ; Xue S; Qin H; Zhao XJ; Zhang M; Liu XQ; Zhu SY; Jiang HD
J Thorac Dis; 2016 Nov; 8(11):3063-3074. PubMed ID: 28066584
[TBL] [Abstract][Full Text] [Related]
8. Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays.
Hamm J; Mahapatra D; Knuth MM; Abedini J; Lingerfelt M; Ekins S; Kullman SW
Curr Res Toxicol; 2022; 3():100092. PubMed ID: 36353521
[TBL] [Abstract][Full Text] [Related]
9. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis.
Peng Z; Raufman JP; Xie G
PLoS One; 2012; 7(10):e48461. PubMed ID: 23119029
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor FXR impairs SK-Hep-1 cell migration and invasion by inhibiting the Wnt/β-catenin signaling pathway.
Li Q; Li N; Zeng Y; Wang X; Li J; Su H; Gao M; Huang X
Oncol Lett; 2020 Nov; 20(5):161. PubMed ID: 32934729
[TBL] [Abstract][Full Text] [Related]
11. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
Sun L; Cai J; Gonzalez FJ
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
[TBL] [Abstract][Full Text] [Related]
12. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
Zhou W; Anakk S
Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.
Yu J; Li S; Guo J; Xu Z; Zheng J; Sun X
Cell Death Dis; 2020 Aug; 11(8):640. PubMed ID: 32807788
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor regulates PI
Xu J; Yao X; Li X; Xie S; Chi S; Zhang S; Cao J; Tan B
Fish Physiol Biochem; 2022 Dec; 48(6):1521-1538. PubMed ID: 36210393
[TBL] [Abstract][Full Text] [Related]
16. Bile acid promotes liver regeneration via farnesoid X receptor signaling pathways in rats.
Ding L; Yang Y; Qu Y; Yang T; Wang K; Liu W; Xia W
Mol Med Rep; 2015 Jun; 11(6):4431-7. PubMed ID: 25634785
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
Kainuma M; Takada I; Makishima M; Sano K
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958417
[TBL] [Abstract][Full Text] [Related]
18. (E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells.
Stefela A; Kaspar M; Drastik M; Kronenberger T; Micuda S; Dracinsky M; Klepetarova B; Kudova E; Pavek P
Front Pharmacol; 2021; 12():713149. PubMed ID: 34483922
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.
Han SY; Song HK; Cha JJ; Han JY; Kang YS; Cha DR
Acta Diabetol; 2021 Apr; 58(4):495-503. PubMed ID: 33399988
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in non-steroidal FXR antagonists development for therapeutic applications.
Huang H; Xu Y; Zhu J; Li J
Curr Top Med Chem; 2014; 14(19):2175-87. PubMed ID: 25388534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
